These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2507213)

  • 1. FDA approves marketing of two drugs previously available under treatment IND regulations.
    Clin Pharm; 1989 Sep; 8(9):607. PubMed ID: 2507213
    [No Abstract]   [Full Text] [Related]  

  • 2. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1989 Nov; 262(18):2503. PubMed ID: 2509741
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves treatment IND protocol for use of erythropoietin product in AIDS.
    Clin Pharm; 1989 Sep; 8(9):607. PubMed ID: 2791478
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
    Trebini F; Daniele D; Gillio S; Scarzella L
    Acta Neurol (Napoli); 1985 Oct; 7(5):432-9. PubMed ID: 3933283
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Bihari K
    Adv Neurol; 1984; 40():549-56. PubMed ID: 6421113
    [No Abstract]   [Full Text] [Related]  

  • 6. [A new drug for Parkinson's disease: selegiline (Eldeprine). Copenhagen, January 26-27, 1989].
    D'Anglejan-Chatillon J
    Rev Prat; 1989 Oct; 39(22):1978. PubMed ID: 2510243
    [No Abstract]   [Full Text] [Related]  

  • 7. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987.
    J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595
    [No Abstract]   [Full Text] [Related]  

  • 8. Why another anti-Parkinson drug?
    Shreeve C
    Nurs Mirror; 1984 Feb; 158(9):38-40. PubMed ID: 6422448
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinson's disease: can we influence progression?
    Quinn N
    Br J Hosp Med; 1990 May; 43(5):327. PubMed ID: 2114189
    [No Abstract]   [Full Text] [Related]  

  • 10. Experience with selegiline in the treatment of Parkinson's disease.
    Poewe W; Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of L-deprenyl in Parkinson's disease].
    Zhonghua Yi Xue Za Zhi; 1983 Mar; 63(3):147-9. PubMed ID: 6409375
    [No Abstract]   [Full Text] [Related]  

  • 12. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 13. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 14. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 15. Practical therapeutics: advances in the management of Parkinson's disease.
    Adam AM
    East Afr Med J; 1985 Feb; 62(2):143-6. PubMed ID: 3930202
    [No Abstract]   [Full Text] [Related]  

  • 16. Current controversies in the use of selegiline hydrochloride.
    Lees AJ
    J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
    Tariska I; Gallai M
    Orv Hetil; 1983 Sep; 124(38):2309-14. PubMed ID: 6415577
    [No Abstract]   [Full Text] [Related]  

  • 19. Selegiline and Parkinson's disease. Protective and symptomatic considerations.
    Golbe LI; Langston JW; Shoulson I
    Drugs; 1990 May; 39(5):646-51. PubMed ID: 2112994
    [No Abstract]   [Full Text] [Related]  

  • 20. A new approach to the treatment of Parkinson's disease. Symposium, Turku, Finland, May 27, 1983.
    Acta Neurol Scand Suppl; 1983; 95():1-144. PubMed ID: 6428139
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.